Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 11/20 | 0.65 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.63 |
| ▸ | IMPDH2 | P12268 | 8/20 | 0.45 |
| ▸ | IMPDH1 | P20839 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26887166 | 0.90 | P2RY2 (0.65) | P2RY2P2RY4 | |
| SCHEMBL22316263 | 0.82 | P2RY2 (0.45) | P2RY2P2RY4IMPDH2IMPDH1 | |
| SCHEMBL26887182 | 0.81 | P2RY2 (0.55) | P2RY2P2RY4IMPDH2IMPDH1 | |
| SCHEMBL26658243 | 0.80 | P2RY2 (0.60) | P2RY2P2RY4IMPDH2IMPDH1 | |
| SCHEMBL6886611 | 0.78 | P2RY2 (1.00) | P2RY2P2RY4 | |
| SCHEMBL6394295 | 0.78 | P2RY2 (1.00) | P2RY2P2RY4 | |
| SCHEMBL10953473 | 0.77 | IMPDH2 (0.62) | P2RY2P2RY4IMPDH2IMPDH1 | |
| SCHEMBL22315724 | 0.77 | UMPS (0.45) | — | |
| SCHEMBL26887183 | 0.76 | P2RY2 (0.58) | P2RY2P2RY4IMPDH2IMPDH1 | |
| SCHEMBL26887172 | 0.76 | P2RY2 (0.58) | P2RY2P2RY4IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | JANSSEN BIOPHARMA, LLC | 2023-11-16 | — | — | US | disclosed |
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | JANSSEN BIOPHARMA, LLC | 2023-11-16 | — | — | US | disclosed |
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | JANSSEN BIOPHARMA, LLC | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | PNP, NUDT1, ADAR | P2RY2 1020/4885P2RY4 317/4885IMPDH2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.